论文部分内容阅读
制备并表征了孔径不同的活性炭微球,考察其对糖尿病模型大鼠的治疗作用。通过制备工艺的改良,制得了直径在0.2-0.3mm的活性炭微球。通过对葡萄糖的吸附实验,筛选最优的活性炭微球。采用雄性Sprague-Dawley大鼠腹腔注射链脲佐菌素诱导制得糖尿病大鼠模型。两组大鼠采用每天两次口服灌胃活性炭微球,连续给药30天。通过离体肠段外翻实验法,测定葡萄糖的跨膜透过量。与糖尿病组相比,在服药2周以后,活性炭微球治疗组的血糖水平明显降低,改善血糖耐受量。在肠粘膜侧有活性炭微球存在时,葡萄糖分子的渗透清除率显著增大,尤其是当浆膜侧的葡萄糖浓度较高时(10mg/mL)。筛选得到的活性炭微球BET比表面积为1566m2/g,微孔含量高(0.478cm3/g),球形良好,对葡萄糖吸附率高。作为口服微球制剂,活性炭微球对链脲佐菌素诱导的糖尿病大鼠有治疗作用。
Preparation and characterization of activated carbon microspheres with different pore sizes, investigate its therapeutic effect on diabetic model rats. Through the improvement of the preparation process, activated carbon microspheres with a diameter of 0.2-0.3mm were prepared. Through the glucose adsorption experiments, the best activated carbon microspheres were screened. The diabetic rat model was induced by intraperitoneal injection of streptozotocin in male Sprague-Dawley rats. Two groups of rats were orally administered with activated carbon microspheres orally twice a day for 30 consecutive days. Through the excretory bowel test method to determine the trans-membrane permeation of glucose. Compared with the diabetic group, after 2 weeks of taking the medicine, the blood sugar level of the activated carbon microspheres treatment group was significantly reduced, improving the blood glucose tolerance. In the presence of activated carbon microspheres on the intestinal mucosa side, the osmotic clearance rate of glucose molecules is significantly increased, especially when the serosal-side glucose concentration is high (10 mg / mL). The BET specific surface area of the activated carbon microspheres was 1566m2 / g, the micropore content was high (0.478cm3 / g), the spherical shape was good, and the adsorption rate to glucose was high. As oral microsphere preparation, activated carbon microspheres have a therapeutic effect on streptozotocin-induced diabetic rats.